Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5625_Библиотеки_им_академика_М_И_Перельмана
.pdf
References
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
16 Rosenfeld, L. and Danishefsky, I. (1988). Location of specific oligosaccharides in
heparin in terms of their distance from the protein linkage region in the native
proteoglycan. The Journal of Biological Chemistry 263: 262–266.
17 Yamada, S., Yamane, Y., Tsuda, H. etal. (1998). A major common trisulfated
hexasaccharide core sequence, hexuronic acid(2-sulfate)-glucosamine(N-sulfate)iduronic acid-N-acetylglucosamine-glucuronic sequence, acid-glucosamine(Nsulfate), isolated from the low sulfated irregular region of porcine intestinal
heparin. The Journal of Biological Chemistry 273: 1863–1871.
18 Radoff, S. and Danishefsky, I. (1984). Location on heparin of the oligosaccharide
section essential for anticoagulant activity. The Journal of Biological Chemistry
259: 166–172.
19 Gong, F., Jemth, P., Escobar-Galvis, M.L. etal. (2003). Processing of macromolecular
heparin by heparinase. The Journal of Biological Chemistry 278: 35152–35158.
20 Iacomini, M., Casu, B., Guerrini, M. etal. (1999). “Linkage region” sequences of
heparins and heparan sulfates: detection and quantification by nuclear magnetic
resonance spectroscopy. Analytical Biochemistry 274: 50–58.
21 Bisio, A., Guerrini, M., Yates, E.A. etal. (1997). NMR identification of structural
environment for 2, 3 and 2, 3, 6 trisulfated glucosamine residues in heparin with
high and no affinity for antithrombin. Glycoconjugate Journal 14: 89.
22 Oscarsson, L.-G., Pejler, G., and Lindahl, U. (1989). Location of the antithrombin-
binding sequence in the heparin chain. The Journal of Biological Chemistry 264:
296–304.
23 Pejler, G., Danielsson, A., Björk, I. etal. (1987). Structure and antithrombin
binding properties of heparin isolated from the clams Anomalocardia brasiliana
and Tivela macrolides. The Journal of Biological Chemistry 262: 11413–11421.
24 Mulloy, B., Gray, E., and Barrowcliffe, T.W. (2000). Characterization of
unfractionated heparin: comparison of materials from the last 50 years.
Thrombosis and Haemostasis 84: 1052–1056.
25 Bertini, S., Bisio, A., Torri, G. etal. (2005). Molecular weight determination of
heparin and dermatan sulfate by size exclusion chromatography with a triple
detector array. Biomacromolecules 6: 168–173.
26 Ferro, D.R., Provasoli, A., Ragazzi, M. etal. (1986). Evidence for conformational
equilibrium of the sulfated L-iduronate residue in heparin and in synthetic
heparin mono- and oligo-saccharides: NMR and force-field studies. Journal of the
American Chemical Society 108: 6773–6778.
27 Mulloy, B., Forster, M.J., Jones, C., and Davies, D.B. (1993). N.m.r. and molecular-
modelling studies of the solution conformation of heparin. The Biochemical
Journal 293: 849–858.
28 Das, S.K., Mallet, J.-M., Esnault, J. etal. (2001). Synthesis of conformationally
locked carbohydrates: a skew-boat conformation of l-iduronic acid governs the
antithrombotic activity of heparin. Angewandte Chemie, International Edition 40:
1670–1673.
29 Guerrini, M., Mourier, P.A.J., Torri, G., and Viskov, C. (2014). Antithrombin-
binding oligosaccharides: structural diversities in a unique function?
Glycoconjugate Journal 31 (6, 7): 409–416.
371
11 Carbohydrate-Based Antithrombotics
372
30 Stancanelli, E., Elli, S., Hsieh, P.-H. etal. (2018). Recognition and conformational
properties of an alternative antithrombin binding sequence obtained by
chemoenzymatic synthesis. ChemBioChem 19: 1178–1188.
31 Hricovini, M. and Hricovini, M. (2018). Solution conformation of heparin
tetrasaccharide. DFT analysis of structure and spin–spin coupling constants.
Molecules 23 (11): 3042–3054.
32 Rosenberg, R.D. and Bauer, K.A. (1994). The heparin-antithrombin system: a
natural anticoagulant mechanism. In: Hemostasis and Thrombosis: Basic Principles
and Clinical Practice, 3e (ed. R.W. Colman, J. Hirsh, V.J. Marder, and
E.W. Salzman), 837–860. Philadelphia, PA: JB Lippincott Co.
33 Beurskens, D.M.H., Huckriede, J.P., Schrijver, R. etal. (2020). The anticoagulant
and nonanticoagulant properties of heparin. Thrombosis and Haemostasis 120:
1371–1383.
34 van Boeckel, C.A.A. and Petitou, M. (1993). The unique antithrombin III binding
domain of heparin: a lead to new synthetic antithrombotics. Angewandte Chemie
32: 1671–1690.
35 Hricovini, M., Guerrini, M., Bisio, A. etal. (2001). Conformation of heparin
pentasaccharide bound to antithrombin III. The Biochemical Journal 359:
265–272.
36 Johnson, D.J.D., Li, W., Adams, T.E., and Huntington, J.A. (2006). Antithrombin–
S195A factor Xa-heparin structure reveals the allosteric mechanism of
antithrombin activation. The EMBO Journal 25: 2029–2037.
37 Desai, U.R., Petitou, M., Biörk, I., and Olson, S.T. (1988). Mechanism of heparin
activation of antithrombin: evidence for an induced-fit model of allosteric
activation involving two interaction subsites. Biochemistry 37: 13033–13041.
38 Lima, A.M., Hughes, A.J., Veraldi, N. etal. (2013). Antithrombin stabilisation by
sulfated carbohydrates correlates with anticoagulant activity. Medicinal Chemistry
Communications 4: 870–873.
39 Izaguirre, G., Swanson, R., Roth, R. etal. (2021). Paramount importance of core
conformational changes for heparin allosteric activation of antithrombin.
Biochemistry 60 (15): 1201–1213.
40 Loganathan, D.H., Wang, M., Mallis, L.M., and Linhardt, R.J. (1990). Structural
variation in the antithrombin III binding site region and its occurrence in heparin
from different sources. Biochemistry 29: 4362–4368.
41 Huntington, J.A. (2003). Mechanism of glycosaminoglycan activation of the
serpins in hemostasis. Journal of Thrombosis and Haemostasis 1: 1535–1549.
42 Gray, E., Hogwood, J., and Mulloy, B. (2012). The anticoagulant and
antithrombotic mechanism of heparin. In: Heparin–A Century of Progress (ed.
R. Lever, B. Mulloy, and C.P. Page), 43–61. Berlin/Heidelberg, Germany:
Springer Verlag.
43 Li, W., Johnson, D.J., Esmon, C.T., and Huntington, J.A. (2004). Structure of the
antithrombin-thrombin-heparin ternary complex reveals the antithrombotic
mechanism of heparin. Nature Structural & Molecular Biology 11: 857–862.
44 Al Dieri, R., Wagenvoord, R., van Dedem, G.W. etal. (2003). The inhibition of
blood coagulation by heparins of different molecular weight is caused by a
References
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
common functional motif–the C-domain. Journal of Thrombosis and
Haemostasis 1: 907–914.
45 Mourier, P.A.J., Guichard, O.Y., Herman, F. etal. (2017). New insights in thrombin
inhibition structure–activity relationships by characterization of
octadecasaccharides from low molecular weight heparin. Molecules 22 (3): 428.
46 Wagenvoord, R., Al, D.R., Van, D.G. etal. (2008). Linear diffusion of thrombin and
factor Xa along the heparin molecule explains the effects of extended heparin
chain lengths. Thrombosis Research 122: 237–245.
47 Gray, E. (2012). Standardisation of low-molecular-weight heparin. In: Heparin–A
Century of Progress (ed. R. Lever, B. Mulloy, and C.P. Page), 65–76. Berlin/
Heidelberg, Germany: Springer Verlag.
48 Ofosu, F.A., Sie, P., Modi, G.J. etal. (1987). The inhibition of thrombin-dependent
feedback reactions is critical to the expression of anticoagulant effects of heparin.
The Biochemical Journal 243: 579–588.
49 Beguin, S., Lindhout, T., and Hemker, H.C. (1988). The mode of action of heparin
in plasma. Thrombosis and Haemostasis 60: 457–462.
50 Streusand, V.J., Bjork, I., Gettins, P.G. etal. (1995). Mechanism of acceleration of
antithrombin-proteinase reactions by low affinity heparin. Role of the
antithrombin binding pentasaccharide in heparin rate enhancement. The Journal
of Biological Chemistry 270: 9043–9051.
51 Parker, K.A. and Tollefsen, D.M. (1985). The protease specificity of heparin
cofactor II. Inhibition of thrombin generated during coagulation. The Journal of
Biological Chemistry 260: 3501–3505.
52 Griffith, M.J. (1983). Heparin-catalyzed inhibitor/protease reactions: kinetic
evidence for a common mechanism of action of heparin. Proceedings of the
National Academy of Sciences United States of America 80: 5460–5464.
53 Tollefsen, D.M. and Blank, M.K. (1981). Detection of a new heparin-dependent
inhibitor of thrombin in human plasma. The Journal of Clinical Investigation 68:
589–596.
54 O’Keeffe, D., Olson, S.T., Gasiunas, N. etal. (2004). The heparin binding
properties of heparin cofactor II suggest an antithrombin-like activation
mechanism. The Journal of Biological Chemistry 279 (48): 50267–50273.
55 McGuire, E.A. and Tollefsen, D.M. (1987). Activation of heparin cofactor II by
fibroblast and vascular smooth cells. The Journal of Biological Chemistry 262:
169–175.
56 Jaques, L.B. (1985). Ein neues Konzept seiner Natur und seiner Wirkung. Teil
III. Die klinische Wirkung des Heparins. Hämostaseologie 5: 121–126.
57 Young, E., Wells, P., Holloway, S. etal. (1994). Ex-vivo and in-vitro evidence that
low molecular weight heparins exhibit less binding to plasma proteins than
unfractionated heparin. Thrombosis and Haemostasis 71 (03): 300–304.
58 Lane, D.A. (1989). Heparin binding and neutralizing protein. In: Heparin:
Chemical and Biological Properties. Clinical Applications (ed. D.A. Lane and
U. Lindahl), 363–374. London, UK: Edward Arnold.
59 Schulman, S., Beyth, R.J., Kearon, C., and Levine, M.N. (2008). Hemorrhagic
complications of anticoagulant and thrombolytic treatment: American College of
373
11 Carbohydrate-Based Antithrombotics
374
Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 257S–298S.
60 Ahmed, I., Majeed, A., and Powell, R. (2007). Heparin induced thrombocytopenia:
diagnosis and management update. Postgraduate Medical Journal 83 (983):
575–582.
61 Alban, S., Krauel, K., and Greinacher, A. (2012). The role of sulfated
polysaccharides in the pathogenesis of heparin-induced thrombocytopenia. In:
Heparin-Induced Thrombocytopenia, CRC Press, 5e (ed. T.E. Warkentin and
A. Greinacher), 181–208. Boca Raton, FL: Taylor and Francis Group.
62 Shaughnessy, S.G., Young, E., Deschamps, P., and Hirsh, J. (1995). The effects of
low molecular weight and standard heparin on calcium loss from fetal rat
calvaria. Blood 86: 1368–1373.
63 Merli, G., Vanscoy, G.J., Rihn, T.L. etal. (2001). Applying scientific criteria to
therapeutic interchange: a balanced analysis of low-molecular-weight heparins.
Journal of Thrombosis 11: 247–259.
64 Fareed, J., Fu, K., Yang, L.H., and Hoppensteadt, D.A. (1999). Pharmacokinetics of
low molecular weight heparins in animal models. Seminars in Thrombosis and
Hemostasis 25 (3): 51–55.
65 Guerrini, M. and Bisio, A. (2012). Low-molecular-weight heparins: differential
characterization/physical characterization. In: Heparin–A Century of Progress
(ed. R. Lever, B. Mulloy, and C.P. Page), 127–157. Berlin/Heidelberg, Germany:
Springer Verlag.
66 Linhardt, R.J. and Gunay, N.S. (1999). Production and chemical processing of low
molecular weight heparins. Seminars in Thrombosis and Hemostasis 25 (3): 5–16.
67 Guerrini, M., Guglieri, S., Naggi, A. etal. (2007). Low molecular weight heparins:
structural differentiation by bidimensional nuclear magnetic resonance
spectroscopy. Seminars in Thrombosis and Hemostasis 33: 478–487.
68 Mascellani, G., Guerrini, M., Torri, G. etal. (2007). Characterization of di- and
monosulfated, unsaturated heparin disaccharides with terminal N-sulfated
1,6-anhydro-β-d-glucosamine or N-sulfated 1,6-anhydro-β-d-mannosamine
residues. Carbohydrate Research 342: 835–842.
69 Bisio, A., Vecchietti, D., Citterio, L. etal. (2009). Structural features of low-
molecular-weight heparins affecting their affinity to antithrombin. Thrombosis
and Haemostasis 102 (5): 865–873.
70 Bisio, A., Mantegazza, A., Vecchietti, D. etal. (2015). Determination of the
molecular weight of low-molecular-weight heparins by using high-pressure size
exclusion chromatography on-line with a triple detector array and conventional
methods. Molecules 20: 5085–5098.
71 Fareed, J., Ma, Q., Florian, M. etal. (2003). Unfractionated and low-molecular-
weight heparins, basic mechanism of action and pharmacology. Seminars in
Cardiothoracic and Vascular Anesthesia 7 (4): 357–377.
72 Gerotziafas, G.T., Petropoulou, A.D., Verdy, E. etal. (2007). Effect of the anti-
factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the
phase of thrombin generation. Journal of Thrombosis and Haemostasis 5: 955–962.
References
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
73 Walenga, J. and Lyman, G.H. (2013). Evolution of heparin anticoagulants to
ultra-low-molecular-weight heparins: a review of pharmacologic and clinical
differences and applications in patients with cancer. Critical Reviews in Oncology/
Hematology 88: 1–18.
74 Naggi, A., Gardini, C., Pedrinola, G. etal. (2016). Structural peculiarity and
antithrombin binding region profile ofmucosal bovine and porcine heparins.
Journal of Pharmaceutical and Biomedical Analysis 118: 52–63.
75 Martinez-Gonzalez, J., Vila, L., and Rodriguez, C. (2008). Bemiparin: second
generation, low-molecular-weight heparin for treatment and prophylaxis of
venous thromboembolism. Expert Reviews in Cardiovascular Therapy 6 (6):
793–802.
76 Nader, H.B., Walenga, J.M., Berkowitz, S.D. etal. (1999). Preclinical differentiation
of low molecular weight heparins. Seminars in Thrombosis and Hemostasis
25 (3): 63–72.
77 Fareed, J., Ma, Q., Florian, M. etal. (2004). Differentiation of low molecular-
weight heparins: impact on the future of the management of thrombosis.
Seminars in Thrombosis and Hemostasis 30 (1): 89–104.
78 Bertini, S., Fareed, J., Madaschi, L. etal. (2017). Characterization of PF4-heparin
complexes by photon correlation spectroscopy and zeta potential. Clinical and
Applied Thrombosis/Hemostasis 23 (7): 725–734.
79 Boer, C., Meesters, M.I., Veerhoek, D., and Vonk, A.B.A. (2018). Anticoagulant
and side effects of protamine in cardiac surgery: a narrative review. British Journal
of Anaesthesia 120 (5): 914–927.
80 Viskov, C., Just, M., Laux, V. etal. (2009). Description of the chemical and
pharmacological characteristics of a new hemisynthetic ultra-low-molecularweight heparin, AVE5026. Journal of Thrombosis and Haemostasis 7: 1143–1151.
81 Rico, S., Antonijoan, R.M., Gich, I. etal. (2011). Safety assessment and
pharmacodynamics of a novel ultra low molecular weight heparin (RO-14) in
healthy volunteers–A first-time-in-human single ascending dose study.
Thrombosis Research 127: 292–298.
82 Acostamadiedo, J.M., Iyer, U.G., and Owen, J. (2000). Danaparoid sodium. Expert
Opinion on Pharmacotherapy 1 (4): 803–814.
83 Ibbotson, T. and Perry, C.M. (2002). Danaparoid: a review of its use in
thromboembolic and coagulation disorders. Drugs 62 (15): 2283–2314.
84 Davenport, A. (2012). Alternatives to standard unfractionated heparin for
pediatric hemodialysis treatments. Pediatric Nephrology 27 (10): 1869–1879.
85 Borawski, J., Zbroch, E., Rydzewska-Rosolowska, A. etal. (2007). Sulodexide for
hemodialysis anticoagulation in heparin-induced thrombocytopenia type
II. Journal of Nephrology 20 (3): 370–372.
86 Adiguzel, C., Iqbal, O., Hoppensteadt, D. etal. (2009). Comparative anticoagulant
and platelet modulatory effects of enoxaparin and sulodexide. Clinical and
Applied Thrombosis/Hemostasis 15 (5): 501–511.
87 Lauver, D.A. and Lucchesi, B.R. (2006). Sulodexide: a renewed interest in this
glycosaminoglycan. Cardiovascular Drug Reviews 24 (3, 4): 214–226.
375
11 Carbohydrate-Based Antithrombotics
376
88 Cosmi, B., Cini, M., Legnani, C. etal. (2003). Additive thrombin inhibition by fast
moving heparin and dermatan sulfate explains the anticoagulant effect of
sulodexide, a natural mixture of glycosaminoglycans. Thrombosis Research
109 (5, 6): 333–339.
89 Harenberg, J., Jescheck, M., Acker, M. etal. (1996). Effects of low-molecular-
weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway
inhibitor in healthy volunteers. Blood Coagulation & Fibrinolysis 7 (1): 49–56.
90 Tovar, A.M.F., de Mattos, D.A., Stelling, M.P. etal. (2005). Dermatan sulfate is the
predominant antothrombotic glycosaminoglycan in vessel walls: implications for
a possible physiological function of heparin cofactor II. Biochimica et Biophysica
Acta 1740: 45–53.
91 Linhardt, R.J. and Hileman, R.E. (1995). Dermatan sulfate as a potential
therapeutic agent. General Pharmacology 26 (3): 443–451.
92 Casu, B., Guerrini, M., and Torri, G. (2004). Structural and conformational aspects
of the anticoagulant and antithrombotic activity of heparin and dermatan sulfate.
Current Pharmaceutical Design 10: 939–949.
93 Maimone, M.M. and Tollefsen, D.M. (1991). Structure of a dermatan sulfate
hexasaccharide that binds to heparin cofactor II with high affinity. The Journal of
Biological Chemistry 119: 653–661.
94 Mascellani, G., Liverani, L., Bianchini, P. etal. (1993). Structure and contribution
to the heparin cofactor Il-mediated inhibition of thrombin of naturally
oversulphated sequences of dermatan sulphate. The Biochemical Journal 296:
639–648.
95 Mascellani, G., Liverani, L., Prete, A. etal. (1994). Quantitation of
dermatansulfate active site for heparin cofactor II by 1H nuclear magnetic
resonance spectroscopy. Analytical Biochemistry 223: 135–141.
96 Pavão, M.S.G., Aiello, K.R., Werneck, C.C. etal. (1998). Highly sulfated
dermatan sulfates from Ascidians. Structure versus anticoagulant activity of
these glycosaminoglycans. The Journal of Biological Chemistry 273:
2748–27857.
97 Pavão, M.S.G., Mourão, P.A.S., Mulloy, B., and Tollefsen, D.M. (1995). A unique
dermatan sulfate- like glycosaminoglycan from ascidian. Its structure and the
effect of its unusual sulfation pattern on anticoagulant activity. The Journal of
Biological Chemistry 270: 31027–31036.
98 Di Carlo, V., Agnelli, G., Prandoni, P. etal. (1999). Dermatan sulphate for the
prevention of postoperative venous thromboembolism in patients with cancer.
DOS (Dermatan sulphate in Oncologic Surgery) Study Group. Thrombosis
Haemostasis 82 (1): 30–34.
99 Vitale, C., Verdecchia, C., Bagnis, C. etal. (2008). Effects of dermatan sulfate for
anticoagulation in continuous renal replacement therapy. Journal of Nephrology
21 (2): 205–212.
100 Vitale, C., Berutti, S., Bagnis, C. etal. (2013). Dermatan sulfate: an alternative to
unfractionated heparin for anticoagulation in hemodialysis patients. Journal of
Nephrology 26 (1): 158–163.
References
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
101 Sié, P., Dupouy, D., Caranobe, C. etal. (1993). Antithrombotic properties of a
dermatan sulfate hexadecasaccharide fractionated by affinity for heparin cofactor
II. Blood 81: 1771–1777.
102 Dol, F., Petitou, M., Lormeau, J.C. etal. (1990). Pharmacologic properties of a low
molecular weight dermatan sulfate: comparison with unfractionated dermatan
sulfate. The Journal of Laboratory and Clinical Medicine 115 (1): 43–51.
103 Barbanti, M., Calanni, F., Milani, M.R. etal. (1993). Therapeutic effect of a low
molecular weight dermatan sulphate (Desmin 370) in rat venous
thrombosis–evidence for an anticoagulant-independent mechanism. Thrombosis
and Haemostasis 69: 147–151.
104 Volpi, N. (1993). “Fast moving” and “slow moving” heparins, dermatan sulfate,
and chondroitin sulfate: qualitative and quantitative analysis by agarose-gel
electrophoresis. Carbohydrate Research 247: 263–278.
105 Veraldi, N., Guerrini, M., Urso, E. etal. (2018). Fine structural characterization of
sulodexide. Journal of Pharmaceutical and Biomedical Analysis 156: 67–79.
106 Coccheri, S. and Mannello, F. (2014). Development and use of sulodexide in
vascular diseases: implications for treatment. Drug Design, Development and
Therapy 4 (8): 49–65.
107 Hoppensteadt, D.A. and Fareed, J. (2014). Pharmacological profile of sulodexide.
International Angiology 33: 229–235.
108 Andreozzi, G.M., Bignamini, A.A., Davì, G. etal. (2015). Sulodexide for the preven-
tion of recurrent venous thromboembolism. The sulodexide in secondary prevention
of recurrent deep vein thrombosis (SURVET) study: a multicenter, randomized,
double-blind, placebo-controlled trial. Circulation 132: 1891–1897.
109 Gardini, C., Urso, E., Guerrini, M. etal. (2017). Characterization of danaparoid
complex extractive drug by an orthogonal analytical approach. Molecules 22:
1116–1141.
110 Meuleman, D.G. (1992). Orgaran (Org 10172): its pharmacological profile in
experimental models. Haemostasis 22 (2): 59–65.
111 Wilde, M.I. and Danaparoid, M.A. (1997). A review of its pharmacology and
clinical use in the management of heparin-induced thrombocytopenia. Drugs
54 (6): 903–924.
112 De Pont, A.-C.J.M., Hofstra, J.-J.H., Pik, D.R. etal. (2007). Pharmacokinetics and
pharmacodynamics of danaparoid during continuous venovenous hemofiltration:
a pilot study. Critical Care 11: R102.
113 Vittoria, A., Messa, G.L., Frigerio, C. etal. (1988). Effect of a single dose of
mesoglycan on the human fibrinolytic system, and the profibrinolytic action of
nine daily doses. International Journal of Tissue Reactions 10 (4): 261–266.
114 Tufano, A., Arturo, C., Cimino, E. etal. (2010). Mesoglycan: clinical evidences for
use in vascular diseases. International Journal of Vascular Medicine 2010 (4):
390643.
115 Neri, G., Marcelli, V., Califano, L., and Investigators, G. (2018). Assessment of the
effect of mesoglycan in the treatment of audiovestibular disorders of vascular
origin. International Journal of Immunopathology and Pharmacology 32: 1–5.
377
11 Carbohydrate-Based Antithrombotics
378
116 Niada, R., Mantovani, M., Prino, G. etal. (1981). Antithrombotic activity of a
polydeoxyribonucleotidic substance extracted from mammalian organs: a possible
link with prostacyclin. Thrombosis Research 23 (3): 233–246.
117 Pescador, R., Capuzzi, L., Mantovani, M. etal. (2013). Defibrotide: properties and
clinical use of an old/new drug. Vascular Pharmacology 59 (1, 2): 1–10.
118 Baker, D.E. and Demaris, K. (2016). Defibrotide. Hospital Pharmacy 51 (10):
847–854.
119 Stein, C., Castanotto, D., Krishnan, A., and Nikolaenko, L. (2016). Defibrotide
(Defitelio): a new addition to the stockpile of Food and Drug Administrationapproved oligonucleotide drugs. Molecular Therapy–Nucleic Acids 5 (8): e346.
120 Bracht, F. and Schror, K. (1994). Isolation and identification of aptamers from
defibrotide that acts as thrombin antagonists invitro. Biochemical and Biophysical
Research Communications 200: 933–937.
121 Richardson, P.G., Carreras, E., Iacobelli, M., and Nejadnik, B. (2018). The use of
defibrotide in blood and marrow transplantation. Blood Advances 2 (12):
1495–1509.
122 Mohty, M., Malard, F., Abecasis, M. etal. (2020). Prophylactic, preemptive, and
curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in
adult patients: a position statement from an international expert group. Bone
Marrow Transplantation 55: 485–495.
123 de Ferra, L., Naggi, A., Zenoni, M., and Pinto, B. (2014). Patent WO 2014114723
A1: method for the qualification of preparations of pentosan polysulfate, raw
materials and production processes thereof.
124 Scheller, H. and Ulvskov, P. (2010). Hemicelluloses. Annual Review of Plant
Biology 61: 263–289.
125 Alekseeva, A., Raman, R., Eisele, G. etal. (2020). In-depth structural
characterization of pentosan polysulfate sodium complex drug using orthogonal
analytical tools. Carbohydrate Polymers 234: 115913–115926.
126 Fischer, A.M., Merton, R.E., Marsh, N.A. etal. (1982). A comparison of pentosan
polysulfate and heparin. II: effect of subcutaneous injection. Thrombosis and
Haemostasis 30: 109–113.
127 Mulholland, S.G., Hanno, P., Parsons, C.L. etal. (1990). Pentosan polysulfate
sodium for therapy of interstitial cystitis: a double-blind placebo-controlled
clinical study. Urology 35 (6): 552–558.
128 Parson, C.L., Benson, G., Childs, S.J. etal. (1994). A Quantitatively controlled
method to study prospectively interstitial cystitis and demonstrate the efficacy of
pentosanpolysulfate. The Journal of Urology 150: 845–848.
129 Sandem, C., Mori, M., Jogdand, P. etal. (2017). Broad Th2neutralization and
anti-inflammatory action of pentosan polysulfate sodium in experimental allergic
rhinitis. Immunity, Inflammation and Disease 5 (3): 300–309.
130 Dunn, F., Soria, J., Soria, C. etal. (1983). Fibrinogen binding on human platelets:
influence of different heparins and pentosan polysulphate. Thrombosis Research
29: 141–148.
References
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
131 Soria, C., Soria, J., Rijckewaart, J.J. etal. (1980). Anticoagulant activities of a
pentosan polysulphate: comparison with standard heparin and a fraction of low
molecular heparin. Thrombosis Research 19: 455–463.
132 Ofosu, F.A., Blajchman, M.A., Modi, G.J. etal. (1985). The importance of
thrombin inhibition for the expression of the anticoagulant activities of heparin,
dermatan sulphate, low molecular weight heparin and pentosan polysulphate.
British Journal of Haematology 60: 695–704.
133 Teichman, J.M. (2002). The role of pentosan polysulfate in treatment approaches
for interstitial cystitis. Revista de Urología 1 (1): S21–S27.
134 Anderson, V.A. and Perry, C.M. (2006). Pentosan polysulfate: a review of its use in
the relief of bladder pain or discomfort in interstitial cystitis. Drugs 66 (6):
821–835.
135 Petitou, M., Casu, B., and Lindahl, U. (2003). 1976–1983, a critical period in the
history of heparin: the discovery of the antithrombin binding site. Biochimie 85
(1–2): 83–89.
136 Sinaÿ, P., Jaquinet, J.-C., Petitou, M. etal. (1984). Total synthesis of a heparin
pentasaccharide fragment having high affinity for antithrombin III. Carbohydrate
Research 132 (2): c5–c9.
137 van Boeckel, C.A.A., Beetz, T., Vos, N.J. etal. (1985). Synthesis of a
pentasaccharide corresponding to the antithrombin III binding fragment of
heparin. Journal of Carbohydrate Chemistry 4 (3): 293–321.
138 Petitou, M., Duchaussoy, P., Lederman, I. etal. (1987). Synthesis of heparin
fragments: a α-methyl pentaoside with high affinity for antithrombin
III. Carbohydrate Research 167: 67–75.
139 Paolucci, F., Claviés, M.-C., François, D., and Necciari, J. (2012). Fondaparinux
sodium mechanism of action: identification of specific binding to purified and
human plasma-derived proteins. Clinical Pharmacokinetics 41: 11–18.
140 Bauer, K.A., Hawkins, D.W., Peters, P.C. etal. (2002). Fondaparinux, a synthetic
pentasaccharide: the first in a new class of antithrombotic agents–the selective
factor Xa inhibitors. Cardiovascular Drug Reviews 20 (1): 37–52.
141 Nutescu, E.A., Burnett, A., Fanikos, J. etal. (2016). Pharmacology of
anticoagulants used in the treatment of venous thromboembolism. Journal of
Thrombosis and Thrombolysis 41: 15–31.
142 Petitou, M. and van Boeckel, C.A.A. (2004). A synthetic antithrombin III binding
pentasaccharide is now a drug! What comes next? Angewandte Chemie 43:
3118–3133.
143 Petitou, M., Duchaussoy, P., Herbert, J.-M. etal. (2002). The synthetic
pentasaccharide fondaparinux: first in the class of antithrombotic agents that
selectively inhibit coagulation factor Xa. Seminars in Thrombosis Research 28 (4):
393–402.
144 Walenga, J., Jeske, W., Samama, M.M. etal. (2002). Fondaparinux: a synthetic
heparin pentasaccharide as a new antithrombotic agent. Expert Opinion on
Investigational Drugs 11 (3): 397–407.
379
11 Carbohydrate-Based Antithrombotics
380
145 Rauova, L., Poncz, M., McKenzie, S.E. etal. (2005). Ultralarge complexes of PF4
and heparin are central to the pathogenesis of heparin-induced
thrombocytopenia. Blood 105 (1): 131–138.
146 Dey, S., Lo, H.-J., and Wong, C.-H. (2020). Programmable one-pot synthesis of
heparin pentasaccharide fondaparinux. Organic Letters 22 (12): 4638–4642.
147 Chen, C. and Yu, B. (2009). Efficient synthesis of Idraparinux, the anticoagulant
pentasaccharide. Bioorganic & Medicinal Chemistry 19 (14): 3875–3879.
148 Harenberg, J. (2010). Idraparinux and Idrabiotaparinux. Expert Review of Clinical
Pharmacology 3 (1): 9–16.
149 Savi, P., Herault, J.P., Duchaussoy, P. etal. (2008). Reversible biotinylated
oligosaccharides: a new approach for a better management of anticoagulant
therapy. Journal of Thrombosis and Haemostasis 6: 1697–1706.
150 Petitou, M., Nancy-Portebois, V., Dubreucq, G. etal. (2009). From heparin to
EP217609: The long way to a new pentasaccharide-based neutralizable
anticoagulant with an unprecedented pharmacological profile. Thrombosis and
Haemostasis 102: 804–810.
151 Gueret, P., Combe, S., Krezel, C. etal. (2016). First in man study of EP217609, a
new long-acting, neutralisable parenteral antithrombotic with a dual mechanism
of action. European Journal of Clinical Pharmacology 72 (9): 1041–1050.
152 Hirsh, J., Bauer, K.A., Donati, M.B. etal. (2008). Parenteral anticoagulants:
American College of Chest Physicians Evidence-Based Clinical Practice
Guidelines (8th Edition). Chest 133 (6 Suppl): 141S–159S.
153 Crowther, M.A., Berry, L.R., Monagle, P.T., and Chan, A.K. (2002). Mechanisms
responsible for the failure of protamine to inactivate low-molecular-weight
heparin. British Journal of Haematology 116 (1): 178–186.
154 Bianchini, E.P., Fazavana, J., Picard, V., and Borgel, D. (2011). Development of a
recombinant antithrombin variant as a potent antidote to fondaparinux and other
heparin derivatives. Blood 117 (6): 2054–2060.
155 Lu, G., DeGuzman, F.R., Hollenbach, S.J. etal. (2013). A specific antidote for
reversal of anticoagulation by direct and indirect inhibitors of coagulation factor
Xa. Nature Medicine 19 (4): 446–451.
156 Xu, Y., Masuko, S., Takieddin, M. etal. (2011). Chemoenzymatic synthesis of
homogeneous ultra low molecular weight heparins. Science 334: 498–501.
157 Xu, Y., Pempe, E.H., and Liu, J. (2012). Chemoenzymatic synthesis of heparin
oligosaccharides with both anti-factor Xa and anti-factor IIa activities. The Journal
of Biological Chemistry 287 (34): 29054–29061.
158 Wang, Z., Hsieh, P.-H., Xu, Y. etal. (2017). Synthesis of 3-O-sulfated
oligosaccharides to understand the relationship between structures and functions
of heparan sulfate. Journal of the American Chemical Society 139 (14): 5249–5256.
Соседние файлы в папке Библиотека им академика М.И. Перельмана